

Business Consortium



Mission of AABC

The mission of Alzheimer's Association® Business Consortium (AABC) is to advance Alzheimer's disease research and innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

The members of AABC work in areas of common interest pre-competitively to advance both the field of Alzheimer's research and the goals of its member organizations. AABC members provide leadership and direction to the group's areas of focus, which include but are not limited to: collaborations, recognition and visibility, and knowledge and information sharing.

Contact Kira Sheinerman (ksheinerman@diamirbio.com), Leen Kawas (kawas@m3bio.com) or Jim Hendrix (jhendrix@alz.org) to be added to the membership mailing list.



2018 Election Results

We are proud to announce that Dr. Leen Kawas has been elected to a two-year term as co-chair for AABC. Dr. Kawas is CEO of M3 Biotechnology and will be a great asset to AABC.

Thank you to Dr. Charles Stacey for his service to AABC. Under Dr. Stacey and Dr. Kira Sheinerman's leadership, AABC has grown in membership and hosted events promoting our mission.

Thanks to candidates Dr. Michael Fossel of Telocyte and Josh Cohen of Amylyx. We know they will continue to provide important leadership contributions to AABC.

We look forward to the working with Drs. Kawas and Sheinerman in the upcoming year. Thanks to all AABC members for your continued participation.



Welcome New Members

AABC is growing! We welcome these new members:

» **Alex Zimmerman and Alexander Lin, Ph.D. – BrainSpec**

BrainSpec is a software platform that quantitatively measures brain chemistry using magnetic resonance spectroscopy. BrainSpec provides researchers with useful quantitative neurometabolite data during clinical trials, which enables identification of neurochemical changes indicative of early stages of Alzheimer's disease, as well as monitoring and assessment of novel drug interventions for patients with Alzheimer's disease. [Read more.](#)

» **Andrew Satlin, M.D. – Intra-Cellular Therapies**

Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs — leveraging technology from the lab of Nobel laureate Dr. Paul Greengard — for the treatment of neuropsychiatric and neurodegenerative diseases. [Read more.](#)

» **Matt Rowe, Ph.D.; Takayuki Sato, MSc, MBA; and Alara Alkin MSc – QMENTA**

QMENTA is an advanced medical image storage, processing and visualization company focused on brain data analysis, specifically using MRI and related clinical data. [Read more.](#)



News From AABC Members and Growth Alzheimer's Disease Companies

Neuronascent

November 10, 2017 - Neuronascent, Inc., a biopharmaceutical company focused on oral therapeutics to promote neuron regeneration, announced the European Patent Office issued EU Patent No. 1937252, on October 25, 2017, with claims of compounds and compositions for stimulating neurogenesis and inhibiting neuronal degeneration.

Neuronascent's novel compounds aim to treat numerous neurological conditions in humans, including Alzheimer's disease, Parkinson's disease and psychiatric disorders. The claims cover small molecule candidates and the family around these candidates and their human use, adding to the patent coverage in the U.S. and elsewhere. This patent is exclusively owned by Neuronascent. [Read more.](#)



News From AABC Members and Growth Alzheimer's Disease Companies (Contd.)

DiamiR

November 14, 2017 - DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, announced the publication of "Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases" in [*Alzheimer's Research & Therapy*](#).

The study was conducted in collaboration with researchers at Perelman School of Medicine at the University of Pennsylvania. Specific brain-enriched and inflammation-associated microRNAs were analyzed in 250 blood plasma samples from patients with Alzheimer's disease, Parkinson's disease, frontotemporal dementia, amyotrophic lateral sclerosis and healthy age/sex-matched controls. microRNA classifiers effectively differentiated disease states from control with 83% to 90% accuracy, and from each other with 77% to 93% accuracy across the four indications. The accuracy of detection and differentiation of the four neurodegenerative diseases was further increased by the analysis of brain-enriched microRNA classifiers separately in samples from female and male participants, suggesting that sex-specific assays could yield higher accuracy in diagnosing neurodegenerative diseases. [Read more.](#)

AABC Translational Animal Models Group Update

The AABC Translation Animal Models group — chaired by Joseph Araujo, Intervivo Solutions, and facilitated by Jim Hendrix, Ph.D., Alzheimer's Association director of Global Science Initiatives — has developed a subgroup of members to plan an Animal Models Symposium. In collaboration with MODEL-AD members, the symposium is tentatively scheduled as an ancillary meeting to the fall Alzheimer's Association Research Roundtable. Further information will be available in future correspondence. The symposium aims to understand the history of AD animal models, explore the current state of the science, identify gaps and recommend specific actions in order to develop the next generation of AD animal models.



Schedule of Events for 2018

Webinars TBA

Alzheimer's Association International Conference 2018

Chicago, Illinois, United States

July 22-26

[More Information.](#)



Past Events

Webinar Recap: AABC Ask the Expert

On December 13, James Cappuccio, managing director, Investment Banking, H.C. Wainwright & Co., presented *Investing in AD: 2017 Overview/2018 Outlook*. Slides from the webinar are available on the [AABC webpage](#).



AABC Collaboration

Job postings

The Alzheimer's Association Medical and Scientific Relations Department is hiring two directors of scientific engagement. These positions can be based at the Association's Home Office in Chicago (preferred), or in any major city in the continental US. (If based outside Chicago, office location will be split between remote and the local chapter office.)

Access the job postings for details:

[Director, Scientific Engagement-San Jose, CA](#)

[Director, Scientific Engagement-Waltham, MA](#)

The Jackson Laboratory is hiring an associate research scientist/MODEL-AD center manager. [Learn more](#) about the position and how to apply by using search term 7133.

AABC Collaboration (Contd.)

Call for submissions

To share general posts, ideas, jobs or events in future newsletters, contact April Ross at agross@alz.org.

To help grow AABC, please continue to introduce new members and companies to the group.